| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/05/2010 | US7641901 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 01/05/2010 | CA2473503C Use of modified pyrimidine compounds to promote stem cell migration and proliferation |
| 01/05/2010 | CA2465723C Process for reacting alkaloids and use of the reaction products in the preparation of medicaments |
| 01/05/2010 | CA2426457C Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 01/05/2010 | CA2405796C Methods and compositions for modulating alpha adrenergic receptor activity |
| 01/05/2010 | CA2392081C Pharmaceutically active isoindoline derivatives |
| 01/05/2010 | CA2369884C Transiently immortalized cells for use in gene therapy |
| 01/05/2010 | CA2358948C Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 01/05/2010 | CA2332642C Method for producing or enhancing a t-cell response against a target cell using a complex comprising an hla class i molecule and an attaching means |
| 01/05/2010 | CA2300480C Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| 01/05/2010 | CA2281877C Psca: prostate stem cell antigen |
| 01/05/2010 | CA2175375C Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use |
| 12/31/2009 | US20090326248 for treatment of insulin-like growth factor-1 receptor (IGF-1R) dependent diseases, such as cancer, psoriasis, atherosclerosis and acromegaly; preferred compound is picropodophyllin |
| 12/31/2009 | US20090326239 Fermentative preparation process for and crystal forms of cytostatics |
| 12/31/2009 | US20090326225 Novel Process for the Preparation of Hexacyclic Compounds |
| 12/31/2009 | US20090326206 Single-chain Multiple Antigen-binding Molecule, Its Preparation and Use |
| 12/31/2009 | US20090326068 Therapeutics for Cancer using 3-Bromopyruvate and other Selective Inhibitors of ATP Production |
| 12/31/2009 | US20090326061 Apoptotic and anti-tumor activities of metallo-salens |
| 12/31/2009 | US20090326055 inhibiting the growth, delaying the progression or preventing the recurrence of androgen-independent prostate cancer tumor cells in a human comprising administering 2,2,5,7,8-pentamethyl-6-chromanol; anticarcinogenic agents |
| 12/31/2009 | US20090326052 Promoters exhibiting endothelial cell specificity and methods of using same |
| 12/31/2009 | US20090326047 Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin |
| 12/31/2009 | US20090326045 Compositions and methods for topical delivery of oligonucleotides |
| 12/31/2009 | US20090326038 Method for treating a immunology-related disease |
| 12/31/2009 | US20090326029 Non-cyclic substituted benzimidazole thiophene benzyl ether compounds |
| 12/31/2009 | US20090326026 Tricyclic Compounds Useful as Angiotensin II Agonists |
| 12/31/2009 | US20090326010 Piperidinyl derivative as a modulator of chemokine receptor activity |
| 12/31/2009 | US20090326008 NF-kappa B Inhibitor |
| 12/31/2009 | US20090325996 Camptothecin derivatives and their use |
| 12/31/2009 | US20090325988 Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof |
| 12/31/2009 | US20090325986 Deazapurine Analogs of 1'-Aza-L-Nucleosides |
| 12/31/2009 | US20090325983 New purine derivatives |
| 12/31/2009 | US20090325982 Phosphodiesterase 4 inhibitors |
| 12/31/2009 | US20090325978 Stable lyophilized preparation |
| 12/31/2009 | US20090325974 1,5-diphenylpyrazoles ii as hsp90 inhibitors |
| 12/31/2009 | US20090325972 Novel cinnamaldehyde derivatives having improved solubility in water, a method for preparing the same and a pharmaceutical composition comprising the same |
| 12/31/2009 | US20090325971 Pentacyclic Alkaloid Compounds and Methods of Use Thereof |
| 12/31/2009 | US20090325933 Pyrimidinone Derivatives and Their Use as a Drug |
| 12/31/2009 | US20090325930 Selective estrogen receptor modulator |
| 12/31/2009 | US20090325928 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors |
| 12/31/2009 | US20090325925 Thiophenes and uses thereof |
| 12/31/2009 | US20090325913 Treatment of pain using satraplatin |
| 12/31/2009 | US20090325903 Boronate ester compounds and pharmaceutical compositions thereof |
| 12/31/2009 | US20090325894 Tetracyclic anthraquinones possessing anti-cancer properties |
| 12/31/2009 | US20090325893 Doxorubicin adjuvants to reduce toxicity and methods for using the same |
| 12/31/2009 | US20090325886 Wt1 modified peptide |
| 12/31/2009 | US20090325880 Tnf receptor-like molecules and uses thereof |
| 12/31/2009 | US20090325877 Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer |
| 12/31/2009 | US20090325876 Use of lipid conjugates in the treatment of diseases associated with vasculature |
| 12/31/2009 | US20090325874 Inhibition of inositol 1,4,5-triphosphate receptor calcium channel/cytochrome c interactions and uses thereof |
| 12/31/2009 | US20090325868 Materials And Methods For FOXP3 Tumor Suppression |
| 12/31/2009 | US20090324745 Compositions and methods for nutrition supplementation |
| 12/31/2009 | US20090324744 Effective Antitumor Treatments |
| 12/31/2009 | US20090324741 Injectable polymer-lipid blend |
| 12/31/2009 | US20090324711 Oral Pharmaceutical Composition of Anilinopyrimidine, Preparation and Use Thereof |
| 12/31/2009 | US20090324708 Compound having inhibitory activity on a rho-gtpase cell protein, a process for obtaining the same, pharmaceutical compositions comprising thereof and a method for the treatment of rho-gtpase cell protein-mediated condition |
| 12/31/2009 | US20090324682 Medical stent provided with inhibitors of atp synthesis |
| 12/31/2009 | US20090324632 Methods and reagents for vaccination which generate a CD8 T cell immune response |
| 12/31/2009 | US20090324622 Antibody vaccine conjugates and uses therefor |
| 12/31/2009 | US20090324621 Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| 12/31/2009 | US20090324617 Cancer specific glycans and use thereof |
| 12/31/2009 | US20090324616 Differential cytokine expression in human cancer |
| 12/31/2009 | US20090324604 M-csf specific monoclonal antibody and uses thereof |
| 12/31/2009 | US20090324599 activates FGF receptors, regulates the growth and differentiation of cells within the liver, regulates other cell types following secretion from the liver, plays a role in liver chemotaxis, has an oncogenic activity, or serves as an antigen for generating antibodies; treating diabetes or obesity |
| 12/31/2009 | US20090324598 Method for the treatment of inflammatory disorders |
| 12/31/2009 | US20090324595 Cancer prognostic diagnostic and treatment methods |
| 12/31/2009 | US20090324594 Antibodies With Immune Effector Activity And That Internalize In Folate Receptor Alpha-Positive Cells |
| 12/31/2009 | US20090324592 Compositions and methods for the diagnosis and treatment of tumor |
| 12/31/2009 | US20090324587 Cancer Therapies and Pharmaceutical Compositions Used Therein |
| 12/31/2009 | US20090324579 Anti-apoptotic protein antibodies |
| 12/31/2009 | US20090324569 Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disorders |
| 12/31/2009 | US20090324566 T-Cell Receptor and Nucliec Acid Encoding the Receptor |
| 12/31/2009 | US20090324556 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof |
| 12/31/2009 | US20090324554 Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates |
| 12/31/2009 | US20090324551 Tlr agonists |
| 12/31/2009 | US20090324545 Polymorphic forms of (s)-1-tetrahydrofuran-3-yl-3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)benzyl carbamate |
| 12/31/2009 | US20090324539 CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES |
| 12/31/2009 | US20090324512 Polypeptide constructs for nasal administration |
| 12/31/2009 | US20090324496 Radioactive material for inhibiting cancer and preparation method thereof |
| 12/31/2009 | US20090324491 Diagnosis and Treatment of Cancer Using Anti-EREG Antibody |
| 12/31/2009 | US20090324490 Compositions and methods for the diagnosis and treatment of tumor |
| 12/30/2009 | WO2009158620A2 Signatures and determinants associated with metastasis methods of use thereof |
| 12/30/2009 | WO2009158571A1 Heteroaryl compounds and uses thereof |
| 12/30/2009 | WO2009158526A2 Methods of reducing cellular proliferation by inhibiting acsvl3 |
| 12/30/2009 | WO2009158516A1 Schweinfurthin analogues |
| 12/30/2009 | WO2009158447A2 Materials and methods for suppressing and/or treating neurofibroma and related tumors |
| 12/30/2009 | WO2009158381A1 Novel psymberin derivatives, compositions, and their use as antineoplastic agents |
| 12/30/2009 | WO2009158026A1 Hydrazonamide compounds that modulate hsp90 activity |
| 12/30/2009 | WO2009157938A1 A2b adenosine receptor antagonists for treating cancer |
| 12/30/2009 | WO2009157919A1 SOLUBLE ErbB3 DETECTION, REGULATION AND TREATMENT OF CANCER |
| 12/30/2009 | WO2009157886A1 Antitumoral, antioxidant and immunomodulatory composite agent |
| 12/30/2009 | WO2009157880A1 Pyrazine substituted purines |
| 12/30/2009 | WO2009157799A1 Agent for treating and preventing oncological diseases and a method for the use of said agent (variants) |
| 12/30/2009 | WO2009157628A1 Pharmaceutical composition for treating or preventing cancer comprising triazine compound as an active ingredient |
| 12/30/2009 | WO2009157561A1 Polymer/metal complex composite having mri contrast ability and mri contrasting and/or antitumor composition using the same |
| 12/30/2009 | WO2009157515A1 Pharmaceutical compositions |
| 12/30/2009 | WO2009157505A1 Telomerase inhibitor |
| 12/30/2009 | WO2009157418A1 Carboxylic acid compound |
| 12/30/2009 | WO2009157279A1 Liquid composition comprising cisplatin-coordinating compound |
| 12/30/2009 | WO2009156994A1 Ccl20-specific antibodies for cancer therapy |
| 12/30/2009 | WO2009156863A2 Substituted tricyclic derivatives |